Prognostication of survival using cardiac troponins and N- terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing.

Slides:



Advertisements
Similar presentations
Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.
Advertisements

Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience.
A disease risk index for patients undergoing allogeneic stem cell transplantation by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T. Ho,
Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways.
A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma by Anamarija M. Perry, Teresa.
A Randomized Phase 3 Study of Peripheral Blood Progenitor Cell Mobilization With Stem Cell Factor and Filgrastim in High-Risk Breast Cancer Patients by.
The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma by Thomas E. Witzig,
From: High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study Ann Intern Med. 2004;140(2):85-93.
by Angela Dispenzieri, A. Keith Stewart, Asher Chanan-Khan, S
Treatment of Immunoglobulin Light Chain Amyloidosis
Hypocholesterolemia Is Independently Associated with Decreased Survival in Patients with Primary Myelofibrosis: An Analysis of Lipid Profiles in 558 Myeloproliferative.
The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.
Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics  Rajshekhar Chakraborty, Eli Muchtar,
Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation by Christopher Bredeson, Jennifer.
Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,
The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome by Anita D'Souza, Suzanne.
by Rafael Fonseca, Richard J. Bailey, Gregory J. Ahmann, S
Critiquing Cryos by Morie Gertz Blood Volume 111(11):
Nonmyeloablative conditioning for relapsed follicular lymphoma
Therapy for Relapsed Multiple Myeloma
by Satish Gopal, William A. Wood, Stephanie J. Lee, Thomas C
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.
Autologous Transplantation Therapy for Chronic Myelogenous Leukemia
Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients by William J. Hogan,
Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.
166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials by.
Cost-Effectiveness Analysis of a Risk-Adapted Algorithm of Plerixafor Use for Autologous Peripheral Blood Stem Cell Mobilization  Ivana N.M. Micallef,
Rafael Fonseca MD Chair, Department of Medicine Mayo Clinic in AZ What is the optimal therapeutic approach for MM patients with bor-len relapsed/refractory.
Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole  Megan R. Barajas, Kristen.
Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.
Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.
Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma by Mohammed A. Aljama, M. Hasib Sidiqi, Arjun.
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is.
Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma:
by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T
Vancomycin-Resistant Enterococcus (VRE) Colonization and Blood Stream Infection (BSI): Prevalence, Risk Factors, and Impact on Early Clinical Outcomes.
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma by Angela Dispenzieri,
Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma by Paul M. Barr, Thomas P. Miller, Jonathan W. Friedberg,
Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics  Rajshekhar Chakraborty, Eli Muchtar,
Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego)
The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.
Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation.
Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation  Gita Thanarajasingam, Haesook T. Kim,
Volume 73, Issue 11, Pages (June 2008)
Therapy for Relapsed Multiple Myeloma
Low Levels of Interleukin-1 Receptor Antagonist (IL-1RA) Predict Engraftment Syndrome after Autologous Stem Cell Transplantation in POEMS Syndrome and.
Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines.
Amyloidosis: Recognition, Confirmation, Prognosis, and Therapy
by Santosh L. Saraf, Xu Zhang, Tamir Kanias, James P. Lash, Robert E
New-Onset Lymphopenia Assessed during Routine Follow-up Is a Risk Factor for Relapse Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation.
Peripheral Blood Lymphocyte and Monocyte Recovery and Survival in Acute Leukemia Postmyeloablative Allogeneic Hematopoietic Stem Cell Transplant  Mary.
Infusion of Autograft Natural Killer Cells/CD14+hla-DRDIM Myeloid-Derived Suppressor Cells Ratio Predicts Survival in Non-Hodgkin Lymphoma Undergoing.
Employment Status as an Indicator of Recovery and Function One Year after Hematopoietic Stem Cell Transplantation  Eleshia J. Morrison, Shawna L. Ehlers,
Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines  Stephen.
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 
Immunologic Autograft Engineering and Survival in Non-Hodgkin Lymphoma
A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation  Philippe Armand, Haesook.
Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma by Nidhi Tandon, Surbhi Sidana, S. Vincent Rajkumar,
Treatment of Autoimmune Disease by Intense Immunosuppressive Conditioning and Autologous Hematopoietic Stem Cell Transplantation by Richard K. Burt, Ann.
Early Lymphocyte Recovery Predicts Superior Survival after Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma: A Prospective Study  Luis F.
Praveena Narayanan, Alexandra Wolanskyj, Shawna L. Ehlers, Mark R
Overcoming “aspirin resistance” in MPN
Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis by Mohammed A. Aljama, M. Hasib Sidiqi,
Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients by Marcel W. Bekkenk, Maarten.
Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.
The Incidence and Outcomes of Oral Mucositis Among Allogeneic Stem Cell Transplantation Patients: A Systematic Review and Meta-Analysis  Hafsa Myedah.
Cold agglutinin disease
Presentation transcript:

Prognostication of survival using cardiac troponins and N- terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation by Angela Dispenzieri, Morie A. Gertz, Robert A. Kyle, Martha Q. Lacy, Mary F. Burritt, Terry M. Therneau, Joseph P. McConnell, Mark R. Litzow, Dennis A. Gastineau, Ayalew Tefferi, David J. Inwards, Ivana N. Micallef, Stephen M. Ansell, Luis F. Porrata, Michelle A. Elliott, William J. Hogan, S. Vincent Rajkumar, Rafael Fonseca, Philip R. Greipp, Thomas E. Witzig, John A. Lust, Steven R. Zeldenrust, Denise S. Snow, Susan R. Hayman, Christopher G. A. McGregor, and Allan S. Jaffe Blood Volume 104(6): September 15, 2004 ©2004 by American Society of Hematology

Survival according to circulating cardiac biomarkers. Angela Dispenzieri et al. Blood 2004;104: ©2004 by American Society of Hematology

Survival according to risk scores or stage. Angela Dispenzieri et al. Blood 2004;104: ©2004 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.